Insulet Corporation (NASDAQ:PODD) – Equities researchers at Northcoast Research lifted their Q2 2018 EPS estimates for Insulet Corporation in a note issued to investors on Friday. Northcoast Research analyst E. Snyder now expects that the medical instruments supplier will post earnings per share of $0.00 for the quarter, up from their previous forecast of ($0.01).

A number of other research analysts have also issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $53.00 price target on shares of Insulet Corporation in a research note on Thursday, April 13th. B. Riley reiterated a “neutral” rating and issued a $44.00 price objective on shares of Insulet Corporation in a research note on Tuesday, May 9th. Northland Securities reiterated a “buy” rating and issued a $50.00 price objective on shares of Insulet Corporation in a research note on Tuesday, May 9th. Oppenheimer Holdings, Inc. set a $46.00 price objective on shares of Insulet Corporation and gave the stock a “hold” rating in a research note on Tuesday, May 9th. Finally, BTIG Research upgraded shares of Insulet Corporation from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Wednesday, May 10th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $49.69.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/q2-2018-earnings-forecast-for-insulet-corporation-nasdaqpodd-issued-by-northcoast-research.html.

Shares of Insulet Corporation (PODD) opened at 53.65 on Monday. The company’s market cap is $3.11 billion. Insulet Corporation has a 52-week low of $30.69 and a 52-week high of $55.46. The firm has a 50-day moving average of $50.00 and a 200-day moving average of $44.62.

Insulet Corporation (NASDAQ:PODD) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.88%. The business had revenue of $110 million during the quarter, compared to the consensus estimate of $106.23 million. During the same quarter in the previous year, the firm posted ($0.08) EPS. The firm’s revenue was up 26.0% on a year-over-year basis.

In other news, SVP Michael P. Spears purchased 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The shares were bought at an average price of $40.59 per share, for a total transaction of $101,475.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jessica Hopfield purchased 2,580 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The shares were purchased at an average price of $38.68 per share, for a total transaction of $99,794.40. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 8,080 shares of company stock worth $317,339. 2.60% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Strs Ohio increased its position in Insulet Corporation by 73.9% in the first quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 1,700 shares during the last quarter. SG Americas Securities LLC bought a new position in Insulet Corporation during the second quarter valued at about $180,000. Teacher Retirement System of Texas bought a new position in Insulet Corporation during the first quarter valued at about $201,000. Diversified Trust Co bought a new position in Insulet Corporation during the second quarter valued at about $205,000. Finally, Ameritas Investment Partners Inc. bought a new position in Insulet Corporation during the first quarter valued at about $215,000.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Earnings History and Estimates for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.